J&J: positive results in bladder cancer

(CercleFinance.com) - On Friday Johnson & Johnson announced encouraging results from a Phase 2b study evaluating the efficacy and safety of the investigational monotherapy TAR-200 in patients with BCG-naive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ, who are ineligible for or refuse radical cystectomy.


The high complete response rate and durability of responses observed in patients treated with TAR-200 underscore the potential of this therapeutic approach for HR-NMIBC patients not responding to BCG,' said Joseph Jacob, of Upstate Medical University's Department of Urology and author of the study.

These results reinforce TAR-200's potential to transform the therapeutic landscape and our ongoing commitment to addressing the unmet needs of patients facing this challenging disease, Johnson & Johnson Innovative added.


Copyright (c) 2024 CercleFinance.com. All rights reserved.